The Hindu Business Line : Ranbaxy in pact with Gilead for anti-HIV drug

Ranbaxy Laboratories Ltd has entered into a licensing agreement with Gilead Sciences Inc, covering manufacturing and marketing of Active Pharmaceutical Ingredient (API) and formulations containing Tenofovir Disoproxil Fumarate (TDF).

While the API will be made available to other Gilead licensees in India, TDF formulations can be marketed in 95 developing countries, including India. Both API and formulations will be manufactured at Ranbaxy's manufacturing facilities in India. The licence allows for technology transfer from Gilead to Ranbaxy.

Brand name

Gilead sells TDF under the brand name Viread. TDF is increasingly being seen as an important first line as well as second-line drug for treatment of HIV infection.

Commenting on the development, Ranbaxy's CEO and Managing Director, Mr Malvinder Mohan Singh, said, "We are continuously striving to provide access to high quality, affordable medicines to HIV patients across the developing world. The agreement with Gilead for Tenofovir will greatly help in that endeavour. With Ranbaxy's extensive ground presence and distribution network in most of the developing countries worst afflicted by HIV/AIDS, Tenofovir will quickly reach patients who are in dire need of this drug."

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ashok Leyland launches factory built cab

Reliance finds gas in KG basin

Partner for Sun Pharma's de-merged entity ruled out

Kajaria to double capacity at Bhiwadi plant

Ranbaxy in pact with Gilead for anti-HIV drug

Claris signs pact with Spanish co Juste Pharma

Meet with a difference

Dunlop to resume operations at Sahagunj next month

Two sick cos of Gayatri group may turnaround soon